Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0010825,
umls-concept:C0012634,
umls-concept:C0019693,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0199176,
umls-concept:C0205179,
umls-concept:C0249458,
umls-concept:C0442711,
umls-concept:C1257890,
umls-concept:C1318970,
umls-concept:C1512888,
umls-concept:C1708528,
umls-concept:C2603343
|
| pubmed:issue |
1
|
| pubmed:dateCreated |
1998-1-23
|
| pubmed:abstractText |
Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0022-1899
|
| pubmed:author |
pubmed-author:CoakleyDD,
pubmed-author:CooperDD,
pubmed-author:FeinbergJ EJE,
pubmed-author:FryJJ,
pubmed-author:GillM JMJ,
pubmed-author:GriffithsP DPD,
pubmed-author:HollandF JFJ,
pubmed-author:HollandG NGN,
pubmed-author:HurwitzSS,
pubmed-author:JacobsonM AMA,
pubmed-author:MacGregorR RRR,
pubmed-author:OwensSS,
pubmed-author:PollardR BRB,
pubmed-author:PowderlyWW,
pubmed-author:PowerM EME,
pubmed-author:SattlerF RFR,
pubmed-author:YouleMM
|
| pubmed:issnType |
Print
|
| pubmed:volume |
177
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
48-56
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9419169-AIDS-Related Opportunistic Infections,
pubmed-meshheading:9419169-Acyclovir,
pubmed-meshheading:9419169-Administration, Oral,
pubmed-meshheading:9419169-Adult,
pubmed-meshheading:9419169-Antiviral Agents,
pubmed-meshheading:9419169-CD4 Lymphocyte Count,
pubmed-meshheading:9419169-Cytomegalovirus Infections,
pubmed-meshheading:9419169-Double-Blind Method,
pubmed-meshheading:9419169-Female,
pubmed-meshheading:9419169-Humans,
pubmed-meshheading:9419169-Male,
pubmed-meshheading:9419169-Valine
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
A randomized, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group.
|
| pubmed:affiliation |
Department of Medicine, University of Cincinnati, Ohio 45267-0405, USA. feinbej@email.uc.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|